Compare LCNB & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | CDXS |
|---|---|---|
| Founded | 1877 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.5M | 256.3M |
| IPO Year | 1999 | 2008 |
| Metric | LCNB | CDXS |
|---|---|---|
| Price | $15.97 | $2.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.7K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | 43.82 |
| EPS | ★ 1.63 | N/A |
| Revenue | $6,445,000.00 | ★ $138,590,000.00 |
| Revenue This Year | $8.50 | $7.73 |
| Revenue Next Year | $3.66 | $14.24 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $13.75 | $0.96 |
| 52 Week High | $17.89 | $3.87 |
| Indicator | LCNB | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 64.71 |
| Support Level | $15.92 | $2.37 |
| Resistance Level | $16.44 | $2.83 |
| Average True Range (ATR) | 0.48 | 0.19 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 14.29 | 72.38 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.